John R. Pinion II

2017

In 2017, John R. Pinion II earned a total compensation of $1.9M as Chief Quality Officer and Executive Vice President of Translational Sciences at Ultragenyx Pharmaceutical, a 6% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$170,459
Option Awards$991,208
Salary$412,568
Stock Awards$308,603
Other$36,491
Total$1,919,329

Pinion received $991.2K in option awards, accounting for 52% of the total pay in 2017.

Pinion also received $170.5K in non-equity incentive plan, $412.6K in salary, $308.6K in stock awards and $36.5K in other compensation.

Rankings

In 2017, John R. Pinion II's compensation ranked 5,705th out of 14,666 executives tracked by ExecPay. In other words, Pinion earned more than 61.1% of executives.

ClassificationRankingPercentile
All
5,705
out of 14,666
61st
Division
Manufacturing
2,070
out of 5,768
64th
Major group
Chemicals And Allied Products
641
out of 2,074
69th
Industry group
Drugs
493
out of 1,730
72nd
Industry
Pharmaceutical Preparations
388
out of 1,329
71st
Source: SEC filing on April 27, 2018.

Pinion's colleagues

We found five more compensation records of executives who worked with John R. Pinion II at Ultragenyx Pharmaceutical in 2017.

2017

Emil Kakkis

Ultragenyx Pharmaceutical

Chief Executive Officer

2017

Jayson Dallas

Ultragenyx Pharmaceutical

Chief Commercial Officer and Executive Vice President

2017

Shalini Sharp

Ultragenyx Pharmaceutical

Chief Financial Officer

2017

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officers and Executive Vice President

2017

Karah Parschauer

Ultragenyx Pharmaceutical

General Counsel

News

In-depth

You may also like